S0820 – Phase III A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer.
1. WHAT TYPE OF CANCER? WHAT STAGE?
Colorectal cancers or high-risk adenomas (polyps).
2. WHO IS ELIGIBLE?
Patients with Stage 0, I, II, or III disease that is removed who desire prevention.
3. HOW WILL I BE TREATED?
This study looks at using two drugs for precention — Sulindac, non-steroidal anti-inflammatory, and eflornithine is a drug that has been shown in a preclinical data to have a role in cancer prevention.
For Physicians: More information about this specific trial at clinicaltrials.gov